vendredi 19 juin 2020

Onco Actu du 19 juin 2020

Study shows sedentary behavior independently predicts cancer mortality [MD Anderson Cancer Center] 
Replacing sitting time with 30 minutes of activity associated with lower risk of cancer death.

Cancer treatment: personalised blood tests can better detect DNA from tumours in the body – new research [The Conversation] 
In our recent study, published in Science Translational Medicine, we show that circulating tumour DNA can be detected with very high sensitivity in the blood when we compare it to a profile of the tumour’s genome.

Picking out the sound of tumours [Cancer Research UK] 
In future studies, the team and their collaborators plan to use this technique to measure ctDNA levels in people who are at high risk of developing cancer and hope that the information they will generate can be used to help refine future tests for cancer early detection.

Cancer’s reliance on fat could be targeted with new ‘drugs and diet’ treatment [Institute of Cancer Research] 
Researchers found that targeting cancer’s ability to process fat using a new class of drugs could halt tumour growth in mice, but only when combined with a diet free of fats.

Discovery Of How Cancer Drugs Find Their Targets Could Lead To A New Toolset For Drug Development [Whitehead Institute] 
The new insights in condensate behavior also provided some answers to another question in cancer research: why people become immune to the breast cancer drug tamoxifen.

CRISPR Technique Targeting Tumor Cells Aims to Improve Chemo Efficacy [Genome Web] 
In their study, the researchers also concluded that this technique could eventually be used in many different types of cancer where NRF2 keeps cells resistant to chemotherapy.

FDA also approved a companion diagnostic for pembrolizumab.

Known as IMpassion031, the Phase III study enrolled early-stage triple-negative breast cancer patients who were scheduled for surgery and gave them either Roche’s PD-L1 therapy Tecentriq plus the chemotherapy Abraxane or simply chemotherapy alone.

Results of the IMpassion031 study will be presented at an upcoming medical meeting and will be discussed with global health authorities including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).

The result was achieved in patients with early invasive TNBC regardless of PD-L1 expression, whereas Tecentriq’s current TNBC approval is for PD-L1-positive, metastatic disease.

With new proposal, Trump administration tries to encourage 'value-based' drug deals [Biopharma Dive] 
The proposed changes, laid out in a proposed rule issued by the Centers for Medicare and Medicaid Services, would lower some of the regulatory requirements that drugmakers have complained limit their ability to enter into outcomes-based agreements.

COVID-19 and cancer [Science] 
Many scientists and clinicians are pivoting their cancer research activities to study the impact of SARS-CoV-2 on cancer. The scientific community must ensure that this pause is only temporary, because trials are the only way to make progress in developing new therapies for cancer. 

Nation’s cancer chief warns delays in cancer care are likely to result in thousands of extra deaths in coming years [Washington Post] 
Because of the pandemic, some cancers will be found later when they are harder to cure, he says.